Brain scans reveal how Weight-Loss drugs rewire appetite in teens vs adults
NCT ID NCT07021937
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study investigates how semaglutide (the drug in Ozempic and Wegovy) changes brain activity related to appetite and eating in people with obesity. Researchers will compare teenagers (ages 12–18) and adults (ages 30–45) using brain scans and meal tests to see if the drug affects the brain differently by age. The goal is to understand how these popular weight-loss medications work in the developing brain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If successful, this could reveal how GLP-1 drugs change brain activity in young people with obesity, potentially leading to more tailored treatments.
- What could go wrong
- This is a Phase 3 trial with 120 participants, so results may not apply to everyone. The study focuses on brain scans and appetite measures, not long-term weight outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.